Selank is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-26. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
| Property | Value | Notes |
|---|---|---|
| Dry storage temperature | -20 C or below | Sealed, desiccated, protected from light |
| Solution stability | Hours to days at 2-8 C | Depends on buffer and microbial load |
| Preferred pH range | Near neutral to slightly acidic | Alkaline pH accelerates hydrolysis |
| Main degradation routes | Hydrolysis and deamidation | No cysteine or methionine in sequence |
| Identity confirmation | Electrospray mass spectrometry | Observed mass compared with 751.9 Da |
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
The vast majority of complex life on Earth requires oxygen for its metabolism, but this same oxygen is a highly reactive element that can damage living organisms. Autoxidation leads to the degradation of organic compounds, including living matter. Organisms contain chemicals and enzymes that minimize oxidative damage without interfering with the beneficial effect of oxygen. In general, antioxidant systems either prevent these reactive species from being formed, or remove them, thus minimizing their damage. ROS can have useful cellular functions, such as redox signaling. Thus, ideally, antioxidant systems do not remove oxidants entirely, but maintain them at some optimum concentration. ROS produced in cells include hydrogen peroxide (H2O2), hypochlorous acid (HClO), and free radicals such as the hydroxyl radical (·OH), and the superoxide anion (O2−). The hydroxyl radical is particularly unstable and will react rapidly and non-specifically with most biological molecules. This species is produced from hydrogen peroxide in metal-catalyzed redox reactions such as the Fenton reaction. These oxidants can damage cells by starting chemical chain reactions such as lipid peroxidation, or by oxidizing DNA or proteins. Damage to DNA can cause mutations and possibly cancer, if not reversed by DNA repair mechanisms, while damage to proteins causes enzyme inhibition, denaturation, and protein degradation. The use of oxygen as part of the process for generating metabolic energy produces ROS.
Avanafil is a PDE5 inhibitor approved for erectile dysfunction by the FDA on April 27, 2012 and by EMA on June 21, 2013. Avanafil is sold under the brand names Stendra and Spedra. It was invented at Mitsubishi Tanabe Pharma, formerly known as Tanabe Seiyaku Co., and licensed to Vivus Inc., which partnered with Menarini Group to commercialise Spedra in over forty European countries, Australia, and New Zealand. Metuchen Pharmaceuticals obtained exclusive rights within the United States. Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme found in various body tissues, primarily in the corpus cavernosum penis. Other similar drugs are sildenafil, tadalafil and vardenafil. The advantage of avanafil is that it has very fast onset of action compared with other PDE5 inhibitors. It is absorbed quickly, reaching a maximum serum concentration in about thirty to forty-five minutes. About two-thirds of the participants were able to engage in sexual activity within fifteen minutes.
Coenzyme Q (CoQ) is a quinone and an electron carrier in the mitochondrial electron transport chain (ETC) of eukaryotes and many bacteria. The other name for CoQ is ubiquinone which was assigned by the IUPAC-IUB Commission on Biochemical Nomenclature in 1975 due to its ubiquitous presence from bacteria to humans. In humans the isoprene side chain has ten isoprene units, hence the abbreviation CoQ10. Coenzyme Q is a coenzyme family that is ubiquitous in animals and many Pseudomonadota, a group of gram-negative bacteria. The fact that the coenzyme is ubiquitous gives the origin of its other name, ubiquinone. In humans, the most common form of coenzyme Q is coenzyme Q10, also called CoQ10 () or ubiquinone-10. Coenzyme Q10 is a 1,4-benzoquinone, in which "Q" refers to the quinone chemical group and "10" refers to the number of isoprenyl chemical subunits (shown enclosed in brackets in the diagram) in its tail. In natural ubiquinones, there are from six to ten subunits in the tail, with humans having a tail of 10 isoprene units (50 carbon atoms) connected to its benzoquinone "head". This family of fat-soluble substances is present in all respiring eukaryotic cells, primarily in the mitochondria. Ninety-five percent of the human body's energy is generated this way. Organs with the highest energy requirements—such as the heart, liver, and kidney—have the highest CoQ10 concentrations. There are three redox states of CoQ: fully oxidized (ubiquinone), semiquinone (ubisemiquinone), and fully reduced (ubiquinol).
Sources: en.wikipedia.org
Marshall (born 1944), American chemist, co-inventor of Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometry Archer John Porter Martin (1910–2002), British physical chemist, 1952 Nobel Prize in Chemistry for the invention of partition chromatography Martinus van Marum (1750–1837), Dutch physician, inventor, scientist and teacher, which created the "large electricity machine" Elmer McCollum (1879–1967), American biochemist, known for work of diet on health Edwin McMillan (1907–1991), American physicist, the first to produce a transuranium element, neptunium, 1951 Nobel Prize in Chemistry Lise Meitner (1878–1968), Austrian and Swedish nuclear physicist instrumental in the discovery of nuclear fission Dmitri Ivanovich Mendeleev (1834–1907), Russian chemist, creator of the Periodic table of elements Maud Menten (1879–1960). Canadian biochemist known for early work on enzyme kinetics John Mercer (1791–1866), British dye and fabric chemist who developed mercerisation, a process for treating cotton Robert Bruce Merrifield (1921–2006), solid-phase chemist, 1984 Nobel Prize in Chemistry Julius Lothar Meyer (1830–1895), German chemist, one of the pioneers in developing the earliest versions of the periodic table of the chemical elements Viktor Meyer (1848–1897), German organic and inorganic chemist, known for work on vapour densities
=== Contraindications === Known or suspected mechanical GI obstruction. Known hypersensitivity to lubiprostone or any ingredient in the formulation. The effects on pregnancy have not been studied in humans, but testing in guinea pigs resulted in fetal loss. Lubiprostone is contraindicated in people exhibiting chronic diarrhea, bowel obstruction, or diarrhea-predominant irritable bowel syndrome.
Autism: Oxytocin may play a role in autism and may be an effective treatment for autism's repetitive and affiliative behaviors. Relationship counseling: The use of oxytocin in relationship counseling for well-being has been suggested. Post-traumatic stress disorder: It has been suggested that oxytocin may be a safer option than MDMA for the treatment of PTSD, although oxytocin has less evidence of efficacy.
Sources: en.wikipedia.org
==== Renovation ==== In 1983, in an attempt to draw crowds to the park and raise money for continued maintenance, the BPRC proposed leasing Bryant Park from the city, renovating it, and building a café in the park. The $18 million renovation was to be executed by an alliance between the BPRC, NYPL, and NYC Parks. Restaurateur Warner LeRoy was to operate the eatery, and he planned to build an 80-foot-tall (24 m), 10,500-square-foot (980 m2) glass café on the park's east side adjacent to the library. In addition, the park would include four smaller food kiosks, a reflecting pool and water fountain, and a dedicated security team.
Sickle cell disorders, which are the most prevalent form of hemoglobinopathy. Sickle hemoglobin (HbS) is prone to polymerize when deoxygenated, precipitating within the red blood cell. This damages the RBC membrane resulting in its premature destruction and consequent anemia. Unstable hemoglobin variants are mutations that cause the hemoglobin molecule to precipitate, spontaneously or upon oxidative stress, resulting in hemolytic anemia. Precipitated, denatured hemoglobin can attach to the inner layer of the plasma membrane of the red blood cell (RBC) forming Heinz bodies, leading to premature destruction of the RBC and anemia. Change in oxygen affinity. High or low oxygen affinity hemoglobin molecules are more likely than normal to adopt the relaxed (R, oxy) state or the tense (T, deoxy) state, respectively. High oxygen affinity variants (R state) cause polycythemia (e.g., Hb Chesapeake, Hb Montefiore). Low oxygen affinity variants can cause cyanosis (e.g., Hb Kansas, Hb Beth Israel).
== Further reading == Isenstadt, Alex (March 18, 2025). Revenge: The Inside Story of Trump's Return to Power. Grand Central Publishing. ISBN 978-1538765517. Allen, Jonathan; Parnes, Amie (April 1, 2025). Fight: Inside the Wildest Battle for the White House. William Morrow. ISBN 978-0063438644. Whipple, Chris (April 8, 2025). Uncharted: How Trump Beat Biden, Harris, and the Odds in the Wildest Campaign in History. Harper Influence. ISBN 978-0063386211. Tapper, Jake; Thompson, Alex (May 20, 2025). Original Sin: President Biden's Decline, Its Cover-Up, and His Disastrous Choice to Run Again. Penguin Press. ISBN 979-8217060672. Dawsey, Josh; Pager, Tyler; Arnsdorf, Isaac (July 8, 2025). 2024: How Trump Retook the White House and the Democrats Lost America. Penguin Press. ISBN 978-0593832530. Wolff, Michael (February 25, 2025). All or Nothing: How Trump Recaptured America. Crown. ISBN 978-0593735381.
The three substrates of this enzyme are (S)-lactaldehyde, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are (S)-lactic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (S)-lactaldehyde:NAD+ oxidoreductase. Other names in common use include L-lactaldehyde:NAD+ oxidoreductase, and nicotinamide adenine dinucleotide (NAD+)-linked dehydrogenase. This enzyme participates in pyruvate metabolism.
Sources: en.wikipedia.org
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.
Hydrolysis of peptide bonds and deamidation of arginine and proline residues are the main degradation routes. Alkaline pH and higher temperatures accelerate both processes. Buffered, near-neutral solutions stored cold generally degrade more slowly than unbuffered ones.
Reverse-phase chromatography gives the clearest single view of related impurities and truncated sequences. Mass spectrometry then confirms that the main peak carries the expected mass. Neither test detects enantiomeric impurities, which require a separate chiral assay.
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.